On July 31, 2026, ClinicalTrials.gov listed an update for a trial evaluating somatropin, recombinant human growth hormone (rHGH), in knee osteoarthritis. The study is titled "Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)" and is registered as NCT07036003.
The trial is designated Phase 1/Phase 2 and its current status is listed as active, not recruiting. This means the study is ongoing but is not currently enrolling new participants.
No results have been posted for this trial as part of this update, and no efficacy or safety outcomes are described in the available record. The listing reflects only the trial's current phase and enrollment status as of the update date.
Somatropin recombinant remains classified as an unapproved research compound in this context. This trial update does not indicate any change to that regulatory status. Readers seeking additional information can refer to the official trial registration for further procedural details.
For broader context on this compound, see the linked overview page.